Abstract 472P
Background
Radiological part-solid nodules (PSNs) containing both solid and ground-glass opacity (GGO) component has lower incidence of nodal metastasis and better prognosis than radiological solid nodules. Previous studies demonstrated that risk of recurrence in GGO-predominant PSNs (0< consolidation-to-tumor ratio ≤0.5) was negligible, while recurrence was not rare in solid- predominant PSNs (0.5< consolidation-to-tumor ratio <1). However, the detailed recurrence patterns and the role of adjuvant therapy after recurrence remained unclear in solid-predominant PSNs.
Methods
Patients with cN0 solid-predominant PSNs (0.5< consolidation-to-tumor ratio <1) undergoing surgery from 2008 to 2015 were collected. The exclusion criteria were as follows: (a) adenocarcinoma in situ or minimally invasive adenocarcinoma, (b) history of other malignancy, (c) multiple primary lesions, and (d) positive resection margin. Median follow-up time was 77.0 months. The initial recurrence site and adjuvant treatment data were collected.
Results
This study included 443 solid-predominant PSNs. Postoperative recurrence was diagnosed in 88 patients (19.9%), including 38 (8.6%) distant, 26 (5.9%) locoregional, and 24 (5.4%) combined recurrences. Lymph node metastasis (P=0.011), lymphovascular invasion (P=0.001), and larger solid component size (P=0.007) were independent predictors of postoperative recurrence. Multivariate Cox regression identified older age (P=0.014, HR=1.044) and early recurrence (P<0.001, HR=4.046) as independent predictors of decreased survival in patients who experienced recurrence. EGFR mutation and ALK rearrangement were identified in 44 (50.0%) and 3 (3.4%) patients who experienced recurrence, respectively. Tyrosine kinase inhibitors demonstrated significant advantages over chemotherapy in patients who experienced recurrence. (median overall survival: 75 vs. 52 months, P=0.004).
Conclusions
Radiological solid-predominant PSNs comprise a heterogeneous population. Active follow-up and effective adjuvant treatment is warranted in patients with risk factors of recurrence. Patients with driver mutations can greatly benefit from targeted therapy if recurrence occurs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
238P - Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience
Presenter: Yuki Endo
Session: Poster Display
Resources:
Abstract
239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Presenter: Ryuichi Mizuno
Session: Poster Display
Resources:
Abstract
240P - Efficacy and safety of first-line combination therapy with ipilimumab + nivolumab for metastatic renal cell carcinoma in a single institution in Japan
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
Presenter: Tamojit Chaudhuri
Session: Poster Display
Resources:
Abstract
244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Presenter: Somnath Roy
Session: Poster Display
Resources:
Abstract
245P - The role of TGF-β in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer
Presenter: Ilseya Myagdieva
Session: Poster Display
Resources:
Abstract
246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Presenter: Stephanie Wakeling
Session: Poster Display
Resources:
Abstract
247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities
Presenter: Othman Mohammed
Session: Poster Display
Resources:
Abstract
248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Presenter: Eyad Al Masoud
Session: Poster Display
Resources:
Abstract
249P - The prognostic utility of Progestogen associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)
Presenter: Leen Lataifeh
Session: Poster Display
Resources:
Abstract